Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Using comprehensive genomic profiling among >600,000 patients, scientists identified activating MET tyrosine kinase domain point mutations as putative oncogenic driver across diverse cancers, with a frequency of ~0.5%.